Abstract：
Cancer is one of the diseases with the highest morbidity and mortality rates worldwide, and its therapeutic options are inadequate. The endothelial glycoprotein, also known as CD105, is a type I transmembrane glycoprotein located on the surface of the cell membranes and it is one of the transforming growth factor-β (TGF-β) receptor complexes. It regulates the responses associated with binding to transforming growth factor β1 egg (Activin-A), bone morphogenetic protein 2 (BMP-2), and bone morphogenetic protein 7 (BMP-7). Additionally, it is involved in the regulation of angiogenesis. This glycoprotein is indispensable in the treatment of tumor angiogenesis, and it also plays a leading role in tumor angiogenesis therapy. Therefore, CD105 is considered to be a novel therapeutic target. In this study, we explored the significance of CD105 in the diagnosis, treatment and prognosis of various tumors, and provided evidence for the effect and mechanism of CD105 on tumors.
摘要：
癌症是世界上发病率和死亡率最高的疾病之一,和它的治疗选择是不够的。内皮糖蛋白，也称为CD105,是位于细胞膜表面的I型跨膜糖蛋白,并且是转化生长因子-β(TGF-β)受体复合物之一。它调节与转化生长因子β1卵（激活素-A）结合相关的反应，骨形态发生蛋白2（BMP-2），和骨形态发生蛋白7(BMP-7)。此外,它参与血管生成的调节。这种糖蛋白在肿瘤血管生成的治疗中是不可缺少的,它在肿瘤血管生成治疗中也起着主导作用。因此,CD105被认为是一种新的治疗靶点。在这项研究中,我们探讨了CD105在诊断中的意义，各种肿瘤的治疗和预后，并为CD105对肿瘤的作用和机制提供了证据。
